Compare PCTY & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCTY | GKOS |
|---|---|---|
| Founded | 1997 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 6.0B |
| IPO Year | 2014 | 2015 |
| Metric | PCTY | GKOS |
|---|---|---|
| Price | $105.61 | $142.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 17 | 12 |
| Target Price | ★ $176.59 | $126.92 |
| AVG Volume (30 Days) | ★ 732.7K | 570.0K |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 10.74 | N/A |
| EPS | ★ 1.77 | N/A |
| Revenue | ★ $1,595,221,000.00 | $507,442,000.00 |
| Revenue This Year | $11.52 | $23.32 |
| Revenue Next Year | $7.98 | $27.43 |
| P/E Ratio | $60.93 | ★ N/A |
| Revenue Growth | 13.74 | ★ 32.33 |
| 52 Week Low | $92.99 | $73.16 |
| 52 Week High | $201.97 | $130.23 |
| Indicator | PCTY | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 51.34 | 75.44 |
| Support Level | $100.04 | $80.14 |
| Resistance Level | $106.19 | N/A |
| Average True Range (ATR) | 3.99 | 4.77 |
| MACD | 1.02 | 0.89 |
| Stochastic Oscillator | 79.16 | 91.72 |
Founded in 1997, Paylocity is a cloud-based human capital management and payroll platform servicing midmarket customers. The company's average client size is around 150 employees. Its products help with recruiting and onboarding, payroll, time and labor, human resources, benefits, learning, and performance and compensation workflows. In fiscal 2025, the company generated over $1.5 billion in revenue across more than 41,000 customers.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.